Regeneron Pharmaceuticals, Inc. (REGN)
735.20
+0.39
(+0.05%)
USD |
NASDAQ |
Oct 02, 16:00
735.13
-0.07
(-0.01%)
After-Hours: 20:00
Regeneron Pharmaceuticals Enterprise Value : 70.72B for Oct. 2, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| October 02, 2026 | 70.72B |
| October 01, 2026 | 70.68B |
| September 30, 2026 | 73.11B |
| September 29, 2026 | 72.30B |
| September 28, 2026 | 72.48B |
| September 25, 2026 | 76.19B |
| September 24, 2026 | 77.01B |
| September 23, 2026 | 77.61B |
| September 22, 2026 | 77.83B |
| September 21, 2026 | 77.23B |
| September 18, 2026 | 75.86B |
| September 17, 2026 | 76.33B |
| September 16, 2026 | 74.80B |
| September 15, 2026 | 74.74B |
| September 14, 2026 | 76.77B |
| September 11, 2026 | 75.51B |
| September 10, 2026 | 76.72B |
| September 09, 2026 | 78.21B |
| September 08, 2026 | 78.49B |
| September 04, 2026 | 80.29B |
| September 03, 2026 | 81.92B |
| September 02, 2026 | 82.80B |
| September 01, 2026 | 79.88B |
| August 31, 2026 | 77.33B |
| August 28, 2026 | 76.82B |
| Date | Value |
|---|---|
| August 27, 2026 | 78.22B |
| August 26, 2026 | 78.95B |
| August 25, 2026 | 80.89B |
| August 24, 2026 | 80.37B |
| August 21, 2026 | 80.94B |
| August 20, 2026 | 80.18B |
| August 19, 2026 | 81.64B |
| August 18, 2026 | 78.48B |
| August 17, 2026 | 78.03B |
| August 14, 2026 | 77.78B |
| August 13, 2026 | 78.04B |
| August 12, 2026 | 77.21B |
| August 11, 2026 | 77.11B |
| August 10, 2026 | 78.25B |
| August 07, 2026 | 75.80B |
| August 06, 2026 | 74.54B |
| August 05, 2026 | 74.17B |
| August 04, 2026 | 73.35B |
| August 03, 2026 | 73.21B |
| July 31, 2026 | 73.56B |
| July 30, 2026 | 71.05B |
| July 29, 2026 | 66.61B |
| July 28, 2026 | 66.58B |
| July 27, 2026 | 63.69B |
| July 24, 2026 | 62.53B |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Gilead Sciences, Inc. | 200.90B |
| Alnylam Pharmaceuticals, Inc. | 29.06B |
| Amgen, Inc. | 261.20B |
| Incyte Corp. | 18.68B |
| Vertex Pharmaceuticals, Inc. | 121.99B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 1.297B |
| Revenue (Quarterly) | 4.291B |
| Total Expenses (Quarterly) | 2.994B |
| EPS Diluted (Quarterly) | 12.23 |
| Gross Profit Margin (Quarterly) | 83.68% |
| Profit Margin (Quarterly) | 30.23% |
| Earnings Yield | 5.50% |
| Operating Earnings Yield | 5.30% |
| Normalized Earnings Yield | 5.834 |